Evidence map›Paper›PMID 42395974›Full record

ArticleACS omega2026

Ricardo A Ceriani F, Miguel A Fuentes-Chandia, Tania F Bahamondez-Cañas, Donald D Brown, Paulina A Puebla, Enzo E Seguel, Leticia A Toledo, Rodrigo A Segura-Del-Rio, Carlos F Henríquez-Roldán, Caroline R Weinstein-Oppenheimer

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ricardo A Ceriani FTherapeutic Innovation and Molecular Diagnostics Laboratory, Escuela de Química y Farmacia, Facultad de Farmacia, Universidad de Valparaíso, Valparaíso 2360102,Chile.ORCID https://orcid.org/0009-0005-5789-7490
Miguel A Fuentes-ChandiaDepartment of Biology, Skeletal Research Center, Case Western Reserve University,Cleveland, Ohio 44106-7078, United States.
Tania F Bahamondez-CañasEscuela de Química y Farmacia, Facultad de Farmacia, Universidad de Valparaíso, Valparaíso 2360102,Chile.ORCID https://orcid.org/0000-0002-3261-466X
Donald D BrownInstituto de Biología, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2360102,Chile.
Paulina A PueblaInstituto de Biología, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2360102,Chile.ORCID https://orcid.org/0009-0008-1050-1358
Enzo E SeguelInstitutional Animal Research Facility, Universidad de Valparaíso, Valparaíso 2360102,Chile.ORCID https://orcid.org/0009-0006-7174-7664
Leticia A ToledoInstitutional Animal Research Facility, Universidad de Valparaíso, Valparaíso 2360102,Chile.ORCID https://orcid.org/0009-0000-0457-7454
Rodrigo A Segura-Del-RioInstituto de Química, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2360102,Chile.ORCID https://orcid.org/0000-0003-0928-0021
Carlos F Henríquez-RoldánFacultad de Ciencias de la Vida, Universidad Viña del Mar, Viña del Mar 2520000,Chile.ORCID https://orcid.org/0000-0001-6616-1243
Caroline R Weinstein-OppenheimerTherapeutic Innovation and Molecular Diagnostics Laboratory, Escuela de Química y Farmacia, Facultad de Farmacia, Universidad de Valparaíso, Valparaíso 2360102,Chile.ORCID https://orcid.org/0000-0001-5435-2587

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic wounds represent a significant clinical challenge due to impaired healing and persistent inflammation. Bioactive scaffolds made from natural polymers combined with the hydroalcoholic extract of

methodsA biocomposite scaffold composed of gelatin, chitosan, and hyaluronic acid, incorporating

resultsThe composite exhibited a uniform, porous structure with an average pore size of approximately 200 μm and a high swelling capacity (>3000%) while preserving viscoelasticity with slight mechanical softening, thereby supporting optimal conditions for cell infiltration and exudate retention. The scaffold supported fibroblasts' adhesion and proliferation, showing good biocompatibility. Formulations containing 0.04 and 0.08 mg/mL

conclusionIncorporating

Identifiers

PMID42395974
PMCPMC13325073

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.